News and Announcements
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
- Published October 15, 2024 7:42AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.
This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.
Executive Interviews
The $3.5 Trillion Succession Wave: Why 48% of Australian Business Owners Are About to Destroy Value
Australia’s Largest Wealth Transfer Has No Exit Plan Australian business succession planning is broken. An estimated $3.5 trillion in assets will pass from Baby Boomers to younger generations over the next two decades. The numbers reveal a crisis. 48% of Baby Boomer business owners plan to exit within five years. Only 24% have formal succession […]
The Great Life Science Reset: Why the “Sick Care” Model is Failing
The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.
Australia’s A$4 Trillion Generational Pivot
Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]
Backed By Leading Investment Groups and Family Offices
